1. Home
  2. EPSM vs RNTX Comparison

EPSM vs RNTX Comparison

Compare EPSM & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EPSM

Epsium Enterprise Limited Ordinary Shares

HOLD

Current Price

$1.33

Market Cap

51.6M

Sector

N/A

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.78

Market Cap

47.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EPSM
RNTX
Founded
2010
2001
Country
China
United States
Employees
N/A
10
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.6M
47.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EPSM
RNTX
Price
$1.33
$1.78
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
12.7K
118.7K
Earning Date
05-24-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.04
$1.02
52 Week High
$155.00
$2.22

Technical Indicators

Market Signals
Indicator
EPSM
RNTX
Relative Strength Index (RSI) 42.43 68.65
Support Level $1.31 $1.08
Resistance Level $1.69 $2.18
Average True Range (ATR) 0.12 0.19
MACD 0.01 0.04
Stochastic Oscillator 5.39 81.65

Price Performance

Historical Comparison
EPSM
RNTX

About EPSM Epsium Enterprise Limited Ordinary Shares

Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohol.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: